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BACKGROUND: Although the contrast-enhancing (CE) lesion on T1-weighted MR images is widely used as a surrogate for
glioblastoma (GBM), there are also non-enhancing regions of infiltrative tumor within the T2-weighted lesion, which elude
radiologic detection. Because non-enhancing GBM (Enh−) challenges clinical patient management as latent disease, this
study sought to characterize ex vivometabolic profiles fromEnh− and CEGBM (Enh+) samples, alongside histological and
in vivoMRparameters, to assist in defining criteria for estimating total tumor burden.Methods: Fifty-six patients with newly
diagnosed GBM received a multi-parametric pre-surgical MR examination. Targets for obtaining image-guided tissue
samples were defined based on in vivo parameters that were suspicious for tumor. The actual location from where tissue
samples were obtained was recorded, and half of each sample was analyzed for histopathology while the other half was
scanned using HR-MAS spectroscopy. Results: The Enh+ and Enh− tumor samples demonstrated comparable mitotic
activity, but also significant heterogeneity in microvascular morphology. Ex vivo spectroscopic parameters indicated similar
levels of total choline andN-acetylaspartatebetween thesecontrast-based radiographic subtypesofGBM, andcharacteristic
differences in the levelsofmyo-inositol, creatine/phosphocreatine, andphosphoethanolamine.Analysisof in vivoparameters
at the sample locationswereconsistentwith histological andex vivometabolic data.CONCLUSIONS:Thesimilarity between
ex vivo levels of choline and NAA, and between in vivo levels of choline, NAA and nADC in Enh+ and Enh− tumor, indicate
that these parameters can be used in defining non-invasive metrics of total tumor burden for patients with GBM.
Translational Oncology (2017) 10, 895–903Received 16 June 2017; Revised 24 August 2017; Accepted 28 August 2017
© 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
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Glioblastoma (GBM) is the most common form of infiltrating glioma in
adults and exhibits the highest level of malignancy based upon
histopathologic criteria developed by the World Health Organization [1].
Defining tumor margins for GBM is complicated by its potential for
proliferation and invasion into surrounding parenchyma. Median survival
with standard-of-care treatment is around 14 months [2] and has remained
unchanged over recent years, despite vigorous research into novel therapeutic
agents and whole genome mutational analyses. Given the relatively rapid
course of the disease, patients are routinely examined every 2 months by
magnetic resonance (MR) imaging to discern whether radiographic
progression has occurred and to modify clinical intervention accordingly.
Routine MR examinations exploit the vascular pathology of GBM,
which is characterized by immature and tortuous growth of tumor
microvasculature. This leads to blood–brain barrier (BBB) permeability that
can be interrogated via the leakage of T1-sensitive paramagnetic contrast
agents. The most commonly utilized agent in clinical practice is gadolinium
(Gd) that has been chelated with diethylene triamine pentaacetic acid
(Gd-DTPA) to reduce toxicity to patients [3]. Extravasation of Gd-DTPA
causes a local reduction in the T1 relaxation time and reveals regions of
elevated signal where the BBB is compromised onT1-weightedMR images.
Increased blood volume and vessel permeability within and beyond the
contrast enhancing (CE) lesion can be evaluated using advanced techniques
such as dynamic susceptibility contrast (DSC) and dynamic contrast
enhanced (DCE) perfusion-weighted MR imaging.
The other type of MR data used in the routine evaluation of GBM
is the T2-weighted fluid-attenuated inversion recovery (FLAIR)
image. Regions that are hyperintense on FLAIR imaging and extend
beyond the borders of the CE lesion are referred to as the T2-weighted
(T2w) lesion. Although part of the T2w lesion contains vasogenic
edema and other non-specific changes, there may also be substantial
regions of infiltrative tumor [4]. The recent use of anti-angiogenic
agents has added to the ambiguity in interpreting imaging data, because
they act by diminishing vascular permeability and can cause a reduction
in the size of both the CE and T2w lesions, while not necessarily
changing the number of tumor cells present.
Other imaging modalities that are thought to be associated with
tumor characteristics include diffusion-weighted imaging (DWI) and
metabolic imaging using in vivo 1H MRSI. Although there have been
reports of a linear correlation between tumor cellularity and restricted
diffusivity, it is unclear whether this assumption applies to tumor in
T2w as well as CE lesions. Numerous studies from our own as well as
other groups have demonstrated the ability of 1H MRSI to highlight
areas of tumor in the T2w lesion based upon a combination of
increased levels of choline and reduced levels of NAA [5].
The purpose of this study was to obtain image-guided tumor
samples of enhancing (Enh+) and non-enhancing (Enh−) GBM from
CE and T2w regions, in order to characterize the similarities and
differences between their histological and ex vivo spectroscopic
profiles. By saving the locations where the actual tissue samples were
obtained during surgery, it was also possible to compare the
corresponding in vivo anatomic, 1H MRSI, DWI, and DSC imaging
parameters between these radiographic subtypes of GBM.
Materials and Methods
Patient Population
The institutionally approved study comprised 56 treatment-naïve
patients who underwent surgical resection and whose lesions weresubsequently diagnosed as being GBM by a single pathologist
according to standard histological criteria [1]. Informed consent was
obtained from each patient for the removal of image-guided tissue
samples during surgery.
Preoperative MR Exam
A multiparametric MR examination was conducted within 24
hours prior to surgery using either 1.5- or 3-T whole-body MR
scanners (GE Healthcare Technologies, Milwaukee, WI, USA) with
an 8-channel, phased-array headcoil for signal reception (MRI
Devices, Knaresborough, United Kingdom). The data obtained
included 3-D pre- and post-contrast T1-weighted inversion recovery
spoiled-gradient echo (IRSPGR) images (TR/TE/TI = 8/3/400 ms,
1.5 mm slices, 15o flip angle, 256 × 256 × 124 matrix, 26 × 26 cm2
in-plane field of view) and T2-weighted anatomic FLAIR and fast
spin echo (FSE) images (see Supplementary Material). In 45/56 cases,
diffusion-weighted imaging was acquired in the axial plane with
spin-echo echo-planar-imaging (TR/TE = 1000/108 ms; voxel size,
1.7 × 1.7 × 3 mm3; 6 gradient directions; 4 NEX; b = 1000 s/mm2)
and, in 24/56 cases, lactate (Lac)-edited three-dimensional 1H MRSI
at 3 T. The latter applied point-resolved spectroscopic selection
(PRESS) for volume localization and very selective saturation (VSS)
pulses for lipid (Lip) signal suppression (excited volume, ~80 × 80 ×
40 mm3; overpress factor, 1.5; TR/TE = 1104/144 ms; field of view,
16 × 16 × 16 cm3; nominal voxel size, 1 × 1 × 1 cm3; flyback
echo-planar readout gradient in the superior–inferior direction; 712
dwell points; sweep width, 988 Hz) [6]. DSC perfusion imaging was
acquired in 45/56 cases as a series of T2
*-weighted echo-planar images
(TR/TE/flip angle = 1250–1500 ms/54–56 ms/30–35 degrees,
128 × 128 matrix, 26 × 26 cm field of view, slice thickness = 3–4
mm, 7–15 slices with 60–80 time points) using a 5 ml/s bolus
injection of 0.1 mmol/kg body weight Gd-DTPA (Magnevist,
gadopentetate dimeglumine).
Definition of Targets For Tissue Sampling
In vivo data from the pre-operative examination were transferred to a
Unix workstation and in-house software were applied to derive estimates
of diffusion, spectroscopic and perfusion parameters. Maps of the
apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were
generated on a pixel-by-pixel basis [7]. The 1HMRSI data were processed
as described previously [8] in order to quantify peak heights and areas of
total choline (tCho), creatine (Cr/PCr),N-acetylaspartate (NAA), lactate
(Lac) and lipid (Lip). Maps of the tCho-to-NAA index (CNI) were
derived using an automated iterative linear regression-based algorithm
that sequentially removes outlying values and represents the changes in
tCho and NAA levels relative to the normal voxels from the same subject
[9]. DSC perfusion data were processed to generate estimates of cerebral
blood volume (CBV) by either fitting dynamic curves using a modified
gamma-variate function with leakage correction [10,11] or using a
non-parametric procedure to estimate peak height (PH) and percent
recovery (REC) [12].
Image-Guided Tissue Sampling
One to four tissue targets were identified, based upon observations
from previous studies, as being within the CE or T2w region using (i)
ADC values less than 1.5 times normal appearing white matter, (ii)
CNI values greater than 2, or (iii) CBV values greater than 3. These
targets were superimposed upon the T1-weighted post-contrast
images as spherical regions of interest (ROIs) with a diameter of 5
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(BrainLAB Inc., Munich, Germany).
While it was not always feasible to resect samples from the
pre-defined tissue targets, the surgeon used the image guidance
software to provide samples from the nearest accessible regions. The
actual sample location was saved on the BrainLAB workstation as
both screenshots and files of RAS coordinates relative to the
pre-surgery images; all of the in vivo imaging was registered together
along with the sample location. After excision, the tissue samples were
immediately bisected: half was snap frozen in liquid nitrogen less than
1 min after removal and stored at −80°C for 1H HR-MAS
spectroscopy; the other half was fixed in 10% zinc formalin,
dehydrated by graded ethanols and embedded in Paraplast Plus wax
(McCormick Scientific, St. Louis, MO, USA) using standardized
techniques for pathological analysis.
Definition of In Vivo Parameters
ROIs corresponding to the CE lesion and any area of necrosis
(NEC) were manually segmented on the T1 post-contrast images.4
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Figure 1. Image-guided tissue from a patient with GBM designated
images. Corresponding CPMG 1H HR-MAS spectra for Enh+ (C) andThe T2w lesion was defined as the region of hyperintensity on the
T2-weighted FLAIR image minus the CE lesion and NEC. A brain
region of interest was defined using the brain extraction tool in FSL
[13], and normal-appearing brain (NAB) was defined as the entire
brain minus the lesion and NEC ROIs. Spherical regions with
5-mm-diameter and centered at the coordinates obtained by
BrainLab from the actual site of tissue removal were defined and
visually confirmed as corresponding to the screenshots acquired
during surgery. Histologically-confirmed tumor with greater than
50% contrast-enhancement in the target ROIs was classified as
enhancing GBM (Enh+), while tumor confined to the T2w lesion
was considered non-enhancing GBM (Enh−). Figure 1 depicts
regions of Enh+ (A) and Enh− (B) tumor from a single patient.
In vivo parameters [14] from within sample ROIs were determined
by histogram analysis of pixel intensities. For the anatomic and DWI
parameters, normalized intensity values were obtained by dividing
median intensities in the corresponding ROI by the mode of the
intensity in the ROI from NAB. For the H-1 spectroscopic data,
metabolite levels were obtained by sinc-interpolating these maps to shift (ppm)
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as Enh+ (A) or Enh− (B) on the basis of post-contrast T1 IRSPGR
Enh− (D) tumor samples. NAAG, N-acetylaspartylglutamate.
Table 1. Summary of Patients and Image-Guided Samples of GBM Classified According to
Enhancement Status
GBM
Classification
Number of
Patients
Number of Tissue Samples
Enh+ Enh−
Enh+ 34 56 0
Enh− 11 0 19
Mixed 11 14 13
Total 56 102 (70 32)
Enh+, contrast-enhancing; Enh−, non-enhancing.
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Normalization factors for tCho, Cr and NAA were defined as median
metabolite level values from the subset of ‘normal’ voxels that were
defined from the CNI algorithm. Levels of Lac and Lip were normalized
relative to the NAA in normal voxels. The CBV, PH and REC were
obtained within sample ROIs as described previously [10,12].
Histological Analysis of the Tumor
An experienced neuropathologist evaluated the slides prepared
from tissue samples with hematoxylin and eosin (H&E) stains to
determine the relative contribution of tumor cells to the overall
cellularity. A score of ‘0’ denoted neuropil without tumor; ‘1’
indicated an infiltrating tumor margin containing detectable but not
abundant numbers of tumor cells; ‘2’ denoted a more cellular
infiltrated zone; and ‘3’ denoted highly cellular tumor with relatively
few non-neoplastic cells. Only tissue samples with scores greater
than zero were included in the analysis. Further H&E and
immunohistochemical analyses were performed to determine overall
cellularity, necrosis content, mitoses (MIB-1), hypoxia (CA9), axonal
disruption (SMI-31), and microvascular morphology (Factor VIII)
(see Supplementary Material) [14]. As described in the Supplementary
Material, Factor VIII was used to grademicrovasculaturemorphology as
delicate (resembling normal cerebral vessels), simple microvascular
hyperplasia (circumferential single cell hyperplasia with definitive
lumen), or complex microvascular hyperplasia (circumferential
multi-layered and glomeruloid-type vessels). IDH wild-type status
relevant to establishing some level of molecular homogeneity among
primary GBM was evaluated via the absence of 2-hydroxyglutarate
(2HG) in HR-MAS spectra.
1H HR-MAS Spectroscopy
Tissue samples weighing between 1.11 and 30.42 mg (median,
10.25 mg) were evaluated. A 35-μL zirconia rotor (custom-designed
by Varian, Palo Alto, CA, USA) was used with 3 μL of 99.9%
atom-D deuterium oxide containing 0.75 wt% 3-(trimethylsilyl)pro-
pionic acid (Sigma-Aldrich, St. Louis, MO, USA) for chemical shift
referencing. Data were acquired at 11.7 T at 1°C with a spin rate of
2250 Hz in a 4-mm gHX nanoprobe with a Varian INOVA
500-MHz multi-nuclear spectrometer.
A rotor-synchronized, one-dimensional, Carr–Purcell–Meiboom–Gill
(CPMG) pulse sequence was run with TR/TE = 4 s/144 ms, 512 scans,
40,000 acquired points, 90° pulse and spectral width of 20 kHz for a total
time of 35 min. A relatively long TE was used to maximally suppress the
macromolecular background for purposes of metabolite fitting. The
electronic reference to access in vivo concentrations (ERETIC) method
was used to generate an artificial electronic signal that served as an external
standard for the estimation of metabolite levels [15].
Pre-processing of the spectra was performed in the time domain
using the Java-based Magnetic Resonance User Interface (jMRUI)
[16]. The estimation of relative one-dimensional metabolite levels
[14] was achieved with the semi-parametric algorithm,
high-resolution quantum estimation (HR-QUEST), which fits a
customized basis set of metabolites to the spectrum [17]. The basis set
used in this study comprised spectra from 26 metabolite solutions
commonly studied in the human brain (Sigma-Aldrich): NAA, free
choline (Cho), phosphocholine (PC), glycerophosphocholine (GPC),
ethanolamine (Eth), phosphoethanolamine (PE), creatine/phospho-
creatine (Cr/PCr), myo-inositol (MI), scyllo-inositol (SI), glucose
(Glc), glycine (Gly), total glutathione [tGSH: glutathione(GSH) + glutathione disulfide (GSSG)], glutamate (Glu), glutamine
(Gln), 2HG, γ-aminobutyric acid (GABA), taurine (Tau), hypo-
taurine (hTau), threonine (Thr), acetate (Ace), Lac, alanine (Ala),
betaine (Bet), aspartate (Asp), valine (Val) and succinate (Suc). Total
choline (tCho) was defined as [PC + GPC + Cho] for comparison
with the in vivo data. Only metabolite estimates with Cramer-Rao
errors less than 12% were included in subsequent analyses. In order to
estimate lipid (Lip) content, the area under the methyl Lip resonance,
centered at approximately 0.9 ppm, was evaluated over the interval [0.936
0.850] ppm in MATLAB, and normalized by sample weight and
ERETIC peak area. Figure 1 shows ex vivo spectra corresponding to
regions of Enh+ (Figure 1,A andC) and Enh− (Figure 1,B andD) tumor.
Statistical Analysis
Tissue samples with tumor scores of 1–3 were evaluated according
to a random mixed effects model in R v3.3.2 [18] that accounted for
patients with multiple tissue samples. Odds ratios and P-values are
reported for continuous imaging and histopathological parameters
that were determined to predict enhancement status when accounting
for repeated specimen sampling. Ordinal histopathology parameters
were compared between Enh+ and Enh− tumor samples using a
proportional odds logistic regression model that also accounted for
repeated sampling [19]; mixed effects models of ordinal-valued
outcomes were analyzed with Proc Genmod in SAS v9.2. Pairwise
correlations were assessed for continuous and ordinal variables using
the Pearson product–moment correlation test and Kendall tau rank
correlation, respectively. Each correlation was run 50 times with a
random tumor sample selected per patient upon every iteration; the
mean and standard deviations for tau estimates are reported along
with median P-values. Bonferroni correction was applied for multiple
correlations among 116 derived parameters.Results
Summary of Analyzed Tumor Tissue
As shown in Table 1, a total of 102 tumor samples (70 Enh+, 32
Enh−) were acquired from the 56 subjects that were evaluated.
1H HR-MAS Spectroscopy
To provide a visual comparison between metabolite profiles of Enh+
and Enh− GBM samples, individual spectra were normalized by the
sample weight and ERETIC peak area, then averaged together according
to enhancement status. The composite spectra shown in Figure 2 for
Enh+ (red) and Enh− (blue) GBM reveal the characteristic features of
these distinct radiographic entities. These demonstrate that phosphocho-
line (PC), rather than glycero-phosphocholine (GPC), is the dominant
choline species. Trace levels ofN-acetylaspartate (NAA) and the presence
of hypo-taurine (hTau) in these samples corroborated the pathological
analysis of the tissue. The Enh− tissue samples displayed elevated levels of
4
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(Gly), myo-inositol (MI), and GPC. The Enh+ samples demonstrated
higher methyl lipid (Lip).Table 2. Regional Summary of Continuous Imaging and Histopathological Parameters
MR/histology Parameter Mean ± SE (n)
Enh+ En
HR-MAS a
MI 1.37 ± 0.12 (53) 2
Cr/PCr 1.03 ± 0.10 (52) 1
PE 1.32 ± 0.12 (53) 1
Lip 8.51 ± 1.70 (70) 4
Gly 2.21 ± 0.34 (48) 4
GPC 0.58 ± 0.07 (46) 0
Anatomic
nT1c 1.52 ± 0.01 (68) 0
nFL 1.69 ± 0.01 (67) 1
nFSE 2.17 ± 0.01 (63) 1
Perfusion
nCBV 2.91 ± 0.48 (28) 1
nPH 2.23 ± 0.33 (28) 1
REC (%) 75.94 ± 2.46 (28) 84
Diffusion
Median nADC 1.54 ± 0.01 (53) 1
Median nFA 0.73 ± 0.01 (51) 0
1H MRSI
nCr/PCr 0.51 ± 0.03 (26) 0
nLac 0.52 ± 0.07 (26) 0
nLip 0.86 ± 0.19 (26) 0
CNI 6.75 ± 0.90 (26) 6
Histopathology
MIB-1 (%) 14.86 ± 0.33 (68) 12
Cellularity b (cells) 286 ± 2 (67)
The estimated difference in effect between Enh+ and Enh− (reference) GBM is summarized by the o
a Arbitrary units without correction for T2-dependence.
b Average number of cells per 200X field.Results from the random mixed effects model were consistent with
the visual assessments and are shown in Table 2. Lactate (Lac) was not
considered in the analysis because of its lack of reliability in the ex vivoOdds Ratio (95%
CI)
P-value
h−
.19 ± 0.35 (23) 0.57 (0.39–0.83) 0.003
.48 ± 0.15 (21) 0.44 (0.24–0.82) 0.009
.88 ± 0.28 (24) 0.51 (0.28–0.94) 0.05
.67 ± 0.53 (32) 1.19 (0.99–1.43) 0.07
.34 ± 1.38 (16) 0.86 (0.73–1.00) 0.06
.81 ± 0.13 (21) 0.44 (0.18–1.07) 0.07
.91 ± 0.01 (29) 140 (23–880) 1 × 10−7
.61 ± 0.01 (29) NA NS
.96 ± 0.03 (29) NA NS
.39 ± 0.11 (20) 3.51 (1.46–8.41) 0.005
.23 ± 0.09 (20) 4.31 (1.30–14.30) 0.02
.27 ± 2.27 (20) 0.93 (0.87–1.00) 0.04
.44 ± 0.01 (28) NA NS
.97 ± 0.01 (25) 0.14 (0.02–0.55) 0.01
.93 ± 0.10 (11) 0.22 (0.04–1.26) 0.09
.30 ± 0.06 (11) 17.65 (0.84–370) 0.07
.59 ± 0.14 (11) NA NS
.69 ± 0.84 (11) NA NS
.88 ± 0.23 (30) NA NS
287 ± 6 (30) NA NS
dds ratio/P-value from a mixed effects model.
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Cr/PCr (P = .009), and PE (P = .05) compared to Enh+ samples, with
a similar trend for Gly. Enh+ tumor samples showed a trend toward
elevated methyl Lip (P = .07), but there was no difference observed in
tCho levels (Table 2).
There were significant correlations between a number of metabolites
for either all samples or the Enh+ samples. In particular, levels of
PE were shown to correspond to levels of tCho (P = .0001),
glutamate (Glu, P = .002), threonine (Thr, P = .002), and
alanine (Ala, P = .00002), which were intercorrelated (seeTS
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In Vivo Imaging
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demonstrated clear distinctions between Enh+ versus Enh− tissue,
with the measures of perfusion peak height (nPH, P = .02) and
cerebral blood volume (nCBV, P = .005) being elevated in Enh+
relative to Enh− GBM, while the percent recovery (REC, P = .04)
was found to be reduced in Enh+ GBM, indicating greater leakage
(Table 2). Although the nADC values showed no difference, the
median normalized values of fractional anisotropy (nFA) were lower
in Enh+ (P = .01) relative to Enh− targets (Table 2).
Lactate-edited 1H MRSI data were obtained for a smaller subset of
patients because it was not always possible to add the additional
sequence in the clinical setting and because the selected volume did
not always cover the tissue sample location. The Enh− targets showed
trends toward higher levels of normalized Cr (P = .09) and lower
levels of normalized Lac (P = .07) compared to Enh+ targets, but
with no significant difference in levels of Cho, NAA or Lip (Table 2).
CNI values were elevated in both Enh+ and Enh− samples (Table 2).
There was an inverse correlation between nADC and both tCho (P = .01)
and CNI (P = .007) for all samples (Table S1).
Histopathology
Tumor scores were similar between Enh+ and Enh− GBM, with
only ~12% more Enh+ samples classified as representing maximal
tumor content (Figure 3; Table 3). Mean overall cell densities were
almost identical at 286 (Enh+) versus 287 (Enh−) cells/200x field
(Table 2). There was no significant difference in the MIB-1 indices
for Enh+ and Enh− samples (14.66% versus 12.88% - see Figure 3
and Table 2). Delicate microvasculature predominated in 45% versus
24% of Enh− and Enh+ samples, respectively, and was completely
absent in almost a third of the Enh+ samples (OR, P = .42, 0.08)
(Figure 3; Table 3). Simple microvasculature overwhelmingly
characterized 41% of Enh+ samples compared to 19% of Enh−
samples (OR, P = 2.18, 0.07) (Figure 3; Table 3), while Enh+
samples had relatively higher scores for complex microvasculature
(Figure 3; Table 3). Hypoxia (CA-9) and necrosis scores were not
significantly different with regard to enhancement status, and axonal
disruption (SMI-31) was comparable across all tumor samples.
There were several instances where the histological scores and
values showed similar trends. Although both Enh+ and Enh− samples
independently showed a strong correlation between tumor score andTable 3. Analysis of Regional Histopathological Features With Categorical Scoring
Categorical Features
Histology Parameter Tissue
Region
Number
of
Samples
Frequency Distributio
0 1
Tumor score Enh− 32 0 25
Enh+ 70 0 21
Necrosis Enh− 32 90.6 3
Enh+ 70 75.7 21
Hypoxia Enh− 30 60.0 13
Enh+ 67 37.3 14
AD Enh− 32 15.6 28
Enh+ 69 11.6 21
Delicate vasculature Enh− 31 12.9 25
Enh+ 70 27.1 30
Simple MVH Enh− 31 19.4 38
Enh+ 70 11.4 30
Complex MVH Enh− 31 71.0 9
Enh+ 69 53.6 14
The estimated difference in effect between Enh+ and Enh− (reference) GBM is summarized by th
hyperplasia; NA, not applicable owing to insufficient non-zero scores; NS, not significant.SMI31 (P = .002, 0.004), the majority of correlations related to the
enhancing tissue samples (Table S1). Among Enh+ GBM, tumor score
was inversely correlated with the presence of delicate microvasculature
(P = .01) and positively correlated with CA9 expression (P = .02), while
CA9 correlated with necrosis (P = .009) and had an inverse relationship
with delicate vasculature (P = .005). Microvascular hyperplasia in Enh+
samples was weakly related to MIB-1 (P = .05). Both Enh+ and Enh−
samples showed a relationship between MIB-1 and average cellularity
(P = .002, 0.009).
Discussion
This study characterized the metabolomic profiles of tissue samples
obtained from enhancing and non-enhancing regions in newly
diagnosed GBM that were confirmed to contain tumor by histological
analysis. Ex vivo 1H HR-MAS metabolite levels were similar for tCho
and NAA, but differed for a number of other metabolites that can be
evaluated through in vivo methods utilizing short echo times.
Analysis of the associated histopathology and multi-parametric MR
examinations helped to contextualize and corroborate these findings.
Given the heterogeneity of anatomic images with regard to contrast
extravasation, having non-invasive parameters that can highlight
non-enhancing tumor is of interest for planning surgical resection and
for the ongoing assessment of total tumor burden.
The heterogeneity in ex vivo metabolite expression between Enh+
and Enh− samples may reflect biological differences in the tumor cells
and their microenvironment. While Enh+ samples displayed a trend
toward elevated methyl Lip that has commonly been linked with
necrosis, the chemical profile of Enh− counterparts more closely
resembled the increases in MI, Cr/PCr and Gly that were previously
observed in samples from de novo grade III glioma, which lack
necrosis and have limited microvascular proliferation [21]. Although
failing to reach statistical significance, the trend toward higher levels
of GPC in Enh− GBM is also consistent with the metabolic profile
displayed by grade III glioma. Elevation in the glia-associated
metabolite MI, which has been extensively employed for classifying
infiltrating disease with respect to pathological grade, has also been
reported for regions of tumor that are less malignant or contain gliosis
based upon standard histological criteria [22,23].
From a neurochemical perspective, the metabolomic profile
exhibited by Enh− samples appears to confirm the heterogeneousn of Categorical Scores (%) Random Effect Model Analysis
2 3 Odds Ratio (95% CI) P-value
.0 31.3 43.8 1.47 (0.67–3.23) NS
.4 22.9 55.7
.1 6.3 NA NA NA
.4 2.9 NA
.3 6.7 20.0 NA NA
.9 20.9 26.9
.1 28.1 28.1 1.53 (0.65–3.56) NS
.7 29.0 37.7
.8 16.1 45.2 0.42 (0.16–1.10) 0.08
.0 18.6 24.3
.7 22.6 19.4 2.18 (0.92–5.15) 0.07
.0 17.1 41.4
.7 16.1 3.2 2.14 (0.69–6.65) 0.18
.5 20.3 11.6
e odds ratio/P-value from a random effects model. AD, axonal disruption; MVH, microvascular
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underlying significance of metabolite differences. The heightened
levels of PCr/Cr observed in Enh− samples are likely due to their
greater bioenergetic potential, as PCr contributes a reservoir of
phosphate for rapid ATP generation [24]. Trending levels of Gly, a
non-essential amino acid and inhibitory neurotransmitter that is
commonly found in high-grade glioma [25], are suggestive of
malignant pathology, though no explicit relationship has been
established. Owing to the in vivo overlap between Gly's singlet and
the M-spin resonance of MI centered at ~3.52 ppm, measurements of
these two metabolites may be difficult to distinguish without
application of techniques such as 2D J-resolved spectroscopy and
spectral editing [26].
In assessing the pathobiology of GBM, consideration must also be
given to the unique lipid metabolism that has been demonstrated in
these lesions. Excess lipid has historically been associated with a poor
prognosis for patients [27], and may relate to an aberrant oncogenic
signaling EGFR/PI3K/Akt pathway that promotes lipid metabolism
via the master transcriptional factor SREBP-1 [28]. Previous
HR-MAS investigations suggested that such lipid elevations are
cytoplasmic in origin and indicative of necrosis, which is a
pathological hallmark exclusive to GBM within the WHO criteria
[29–31]. While necrosis was not statistically differentiated in this
study, it was noted as N2.5x more common in Enh+ samples. One of
the above studies additionally revealed that the presence of cholesteryl
esters and triglycerides in cell extracts from GBM was correlated with
the extent of vascular proliferation using both 1H and 13C HR-MAS
techniques [31]. Given the apparent relevance of lipid fractions to
pathology, it is worth noting the elevation of PE in Enh− GBM,
which suggests that there are differences in phospholipid metabolism
associated with the Kennedy pathway [32].
Within Enh+ GBM, PE also showed multiple exceptionally strong
correlations with other metabolites, including tCho and threonine.
Because the cytidine diphophospate (CDP)-ethanolamine (Eth)
pathway represents half of the Kennedy pathway, there are plausible
relations of PE to choline species. The CDP-Eth pathway is
additionally known to regulate diacylglycerol, a key activator of
serine–threonine kinases, thus providing support for the association
with threonine [33].
While limited in coverage and employment, the acquisition of in vivo
1H MRSI data proved valuable for corroborating HR-MAS findings.
Both in vivo and ex vivo spectroscopy demonstrated levels of tCho
that were not statistically different between Enh+ and Enh− tumor,
but nevertheless abnormally elevated relative to NAA, as demon-
strated by the in vivoCNI values. Previous investigations have shown
that the PC resonance forms the dominant contribution to the
in vivo tCho peak in GBM, whether as primary tumor or secondary
tumor that has transitioned from grade II or III glioma [21,34]. Because
ex vivo Lac levels are considered unreliable given the ongoing
metabolism of tissue following extraction, it was instructive to observe
increased in vivo Lac levels in Enh+ GBM. Such increases may be
attributed to heightened anaerobic respiration and/or interpolation of
data with nearby necrosis on account of the coarse spatial resolution of
MRSI.
Among the metabolites that distinguished Enh− samples, Cr/PCr
and MI + Gly offer the greatest promise for in vivo characterization
of differences between contrast-based radiographic subtypes of GBM.
While the ex vivo elevation of Cr/PCr levels in Enh− relative to Enh+
samples was seen as a trend for in vivo 1H MRSI data, the long echotime utilized in the current study prevented the detection of
MI + Gly. Because of the T2-shortening effects from MI's complex
coupling, either a point-resolved spectroscopy (PRESS) sequence with
a TE ≤ 35 ms or some Carr-Purcell-Meiboom-Gill (CPMG)-inspired
sequence would be required for future studies [35].
The differences in vascular physiology assessed by in vivo
perfusion-weighted imaging in this study were found to accurately
reflect the microvascular heterogeneity of GBM represented by Factor
VIII immunostaining. Elevations in nPH and nCBV in Enh+ regions
were consistent with the microvascular hyperplasia and gross
hypervascularity that are associated with angiogenesis, and similar
to the results obtained by Essock-Burns et al. [36]. Reduced REC
within the enhancing tumor is similarly indicative of immature,
perforated vasculature whose permeability provides greater access to the
extravascular, extracellular space. Although Enh+ regions displayed
aberrant perfusion, the in vivo parameters observed in Enh− GBM
remained within the range that is considered normal [37], and therefore
present a challenge for defining total tumor burden.
Analysis of the DWI data indicated that nADC values in tumor
were similar irrespective of enhancement status, with median values
near 1.5 reflecting moderately restricted diffusion. This finding is
supported by the fact that overall cell density and tumor cellularity
were comparable between Enh+ and Enh− samples. The in vivo
nADC was also found to inversely correlate with measures of tCho
and CNI, which inform on tumor cellularity via choline species
involved in membrane turnover. The higher values of nFA exhibited
by Enh− samples demonstrated that non-enhancing components of
the tumor may retain greater integrity of the surrounding tissue
compared to that in the CE lesion, despite no clear differences in
axonal disruption measured via SMI-31. Regardless of the potentially
favorable structural status of Enh− samples, histopathologic analysis
of MIB-1 mitotic indices indicated that there were similar levels of
proliferation as in Enh+ samples. This suggests that Enh− tumor may
bear a high degree of malignancy, even in the absence of patent
contrast extravasation.
Besides providing evidence of comparable proliferation and
cellularity between Enh+ and Enh− samples from GBM, the
histopathology also showed internal relationships among several
parameters. Both types of samples displayed the expected correlations
between tumor score and axonal disruption, as well as between
proliferation and average cellularity. For Enh+ samples, the
association of hypoxia (as estimated by CA-9 scores) with regional
necrosis provided validation of these respective assays. As might be
anticipated, delicate vasculature, which is considered normal from a
histological standpoint, was found to be inversely correlated with
hypoxia for the Enh+ samples.
Conclusion
The results of this study provide extensive characterization of CE and
non-enhancing GBM from image-guided tumor samples. While these
contrast-based subtypes of disease demonstrated comparable mitotic
activity and cellularity, their microvascular morphology provided a
basis for histological differentiation. Given the similarity in ex vivo
tCho and NAA levels measured via HR-MAS spectroscopy, there is
strong evidence to support the use of CNI as a metric for defining
total tumor burden in vivo. The ADC values were also found to be
similar across Enh− and Enh+ GBM, and may be evaluated in
conjunction with CNI as advanced criteria for detection of
non-enhancing disease. Differences in ex vivo levels of Cr/PCr, as
Translational Oncology Vol. 10, No. 6, 2017 Characterization of Non-Enhancing GBM Autry et al. 903well as in the factor VIII scores and in vivo DSC parameters, were
consistent with the expectation that Enh− tumor has more
normal-appearing vasculature. Despite the proven utility of DSC
perfusion in highlighting tumor, the vascular profile of Enh− GBM
was shown to be such that it eludes detection in vivo.
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